STAT3 and hepatocellular carcinoma: Another Phase III trial is also underway for the combination of napabucasin and paclitaxel in gastric and gastroesophageal junction cancers (NCT02178956).278 Unlike small molecule inhibitors, AZD9150 is a siRNA targeting STAT3, showing clinically valuable antitumor activity and can be regarded as a safe treatment for diffuse large B-cell lymphoma.281 A phase I study showed that AZD9150 was well tolerated with mild and a few serious adverse events (NCT01839604) in HCC.279 Nevertheless, further studies are required to illuminate its clinical efficacy.